Abstract | OBJECTIVE: To assess the effectiveness at 21-30 days after treatment of tinidazole administered orally at 1 g once daily for 5 days and 2 g once daily for 2 days, compared with placebo, in the treatment of bacterial vaginosis, using rigorous U.S. Food and Drug Administration (FDA)-recommended criteria to define cure. METHODS: A total of 235 women at 10 U.S. centers participated in this prospective, randomized, double-blinded, placebo-controlled trial. Presence or absence of all five following criteria was required to define diagnosis or cure of bacterial vaginosis: 1) clue cells were at least 20% of squamous cells in microscopic examination of vaginal fluid; 2) positive potassium hydroxide whiff test; 3) a homogeneous, thin, white-gray vaginal discharge; 4) vaginal pH greater than 4.5; and 5) Nugent score greater than or equal to 4 on Gram-stained vaginal fluid. Compliance, tolerability, and safety were assessed using patient diaries and interviews at 8-10 days and 21-30 days after treatment. Cochran-Mantel-Haenszel statistical analysis with Bonferroni adjustment was used to compare outcomes. RESULTS: Superior efficacy was demonstrated by tinidazole for the 1 g once daily for 5 days regimen (36.8% cured, P<.001, number needed to treat 3.2) and for the 2 g once daily for 2 days regimen (27.4% cured, P<.001, number needed to treat 4.5), when compared with placebo (5.1% cured) in the primary endpoint analysis. Using more traditional criteria for cure, efficacy was greater. Compliance with study therapy and tolerability were comparable in the three treatment groups. CONCLUSION: CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00229216 LEVEL OF EVIDENCE: I.
|
Authors | Charles H Livengood 3rd, Daron G Ferris, Harold C Wiesenfeld, Sharon L Hillier, David E Soper, Paul Nyirjesy, Jeanne Marrazzo, Ashwin Chatwani, Paul Fine, Jack Sobel, Stephanie N Taylor, Lindsey Wood, John J Kanalas |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 110
Issue 2 Pt 1
Pg. 302-9
(Aug 2007)
ISSN: 0029-7844 [Print] United States |
PMID | 17666604
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antitrichomonal Agents
- Tinidazole
|
Topics |
- Administration, Oral
- Adult
- Antitrichomonal Agents
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Patient Compliance
- Patient Satisfaction
- Tinidazole
(administration & dosage, adverse effects)
- Treatment Outcome
- Vaginosis, Bacterial
(drug therapy)
|